HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...

Xoma acquired royalty payments and a portion of potential milestones associated with five hematology assets from Aronora. Xoma Corp. (NASDAQ:XOMA) will pay $6 million up front to receive 10% of milestones for each asset plus...

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...

Xoma Corp. (NASDAQ:XOMA) granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab ( XOMA 052 ). The company also granted Novartis a non-exclusive license to IP covering IL-1 beta -targeting...

Novartis AG (NYSE:NVS; SIX:NOVN) said canakinumab (ACZ885) significantly reduced lung cancer incidence and associated mortality vs. placebo in the Phase III CANTOS cardiovascular outcomes trial in patients with a prior heart attack and inflammatory atherosclerosis....

Xoma Corp. (NASDAQ:XOMA) jumped $2.17 (24%) to $11.10 on Friday after granting Novartis AG (NYSE:NVS; SIX:NOVN) worldwide rights to commercialize IL-1 beta mAb candidate gevokizumab (XOMA 052). The company also granted Novartis a non-exclusive license...

Data from 13 patients ages 42-68 with hypoglycemia post-bariatric surgery in an open-label, U.S. Phase II trial showed that single doses of 3, 6 and 9 mg/kg IV XOMA 358 were generally well tolerated. XOMA...

Additional data from an open-label, international Phase II trial in 14 patients ages 12-37 with hypoglycemia associated with congenital hyperinsulinism showed that single doses of IV XOMA 358 reduced the duration of hypoglycemia by 25-70%...

Antibody developer Xoma Corp. (NASDAQ:XOMA) raised $25 million through the sale of 1.2 million shares at $4.03 and 5,003 convertible preferred shares at $4,030 in a registered direct offering to existing investor Biotechnology Value Fund...